Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

IMPORTANCE: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with antiplatelet (AP) drugs in addition to OAC, with or w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Keith A. A., Velentgas, Priscilla, Camm, A. John, Bassand, Jean-Pierre, Fitzmaurice, David A., Gersh, Bernard J., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., Dabrowski, Elizabeth, Luo, Kaiyi, Gibbs, Liza, Kakkar, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137686/
https://www.ncbi.nlm.nih.gov/pubmed/32101311
http://dx.doi.org/10.1001/jamanetworkopen.2020.0107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137686/
https://www.ncbi.nlm.nih.gov/pubmed/32101311
http://dx.doi.org/10.1001/jamanetworkopen.2020.0107

Ejemplares similares